Relmada Therapeutics, Inc. RLMD Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -48.8%+111pp | -94%+38.3pp | -196.8%-80.2pp | -175.1%-74.7pp | -160.3%-64.8pp | |
| Liquidity | ||||||
| Current ratio | 18.3×+13.0× | 14.6×+10.2× | 2.9×-4.0× | 4.1×-3.3× | 5.3×-1.5× | |
| Per Share | ||||||
| Book value per share | $2.53+242% | $2.19+86.1% | $0.29-81.9% | $0.48-76.4% | $0.74-69.1% | |
| Valuation | ||||||
| Market capitalization | $677.17M+2,907% | $354.2M+2,157% | $66.72M-31.8% | $19.65M-78.3% | $8.96M-93.6% | |
| Price / book | 3.1×+2.1× | 4.1×+3.7× | 7×+5.0× | 1.2×-0.2× | 0.4×-1.5× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Relmada Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Relmada Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.